COVID-19 inpatients with psychiatric disorders: Real-world clinical recommendations from an expert team in consultation-liaison psychiatry was written by Anmella, G.;Arbelo, N.;Fico, G.;Murru, A.;Llach, C. D.;Madero, S.;Gomes-da-Costa, S.;Imaz, M. L.;Lopez-Pelayo, H.;Vieta, E.;Pintor, L.. And the article was included in Journal of Affective Disorders in 2020.Recommanded Product: 839712-12-8 This article mentions the following:
Background: The management of coronavirus disease 2019 (COVID-19) in patients with comorbid psychiatric disorders poses several challenges, especially regarding drug interactions. Methods: We report three representative case-scenarios on patients with psychiatric disorders and COVID-19 to provide a practical approach based on the existing literature and the clin. experience of an expert team in consultation-liaison psychiatry. Case-centered recommendations: Psychopharmacol. ongoing treatments should be prioritized and most doses should be reduced 25-50% of original dose if the patient receives lopinavir/ritonavir, with some exceptions including quetiapine, asenapine, olanzapine, sertraline, lamotrigine, bupropion, and methadone. If the psychopharmacol. usual doses are in the low-to-median range levels, a dose change during COVID-19 drugs co-administration is not recommended, but only ECG and clin. monitoring of adverse effects and drug levels if required. Furthermore, when introducing a psychopharmacol. drug, dose titration should be progressive, with ECG monitoring if cardiotoxic interactions are present. (A) In agitated delirium, olanzapine is recommended as first-line antipsychotic and quetiapine should be avoided. (B) In severe mental illness (SMI), essential treatments should be maintained. (C) In non-SMI with depressive/anxiety symptoms, psychol. support should be provided and symptoms identified and treated. Limitations: Most recommendations on pharmacol. interactions provide only a limited qual. approach and quant. recommendations are lacking. Conclusions: Patients with psychiatric disorders and COVID-19 should be managed on a personalized basis considering several clin. criteria and, should not be excluded from receiving COVID-19 treatments. Risks of pharmacol. interaction are not absolute and should be contextualized, and most psychopharmacol. treatments should include an ECG with special attention to QTc interval. In the experiment, the researchers used many compounds, for example, 3-(trans-4-(2-(4-(2,3-Dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl)-1,1-dimethylurea (cas: 839712-12-8Recommanded Product: 839712-12-8).
3-(trans-4-(2-(4-(2,3-Dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl)-1,1-dimethylurea (cas: 839712-12-8) belongs to piperazine derivatives. Piperazine causes primary dermal irritation and skin burns at high concentrations. Piperazine also causes eye irritation in humans. Two common salts in the form of which piperazine is usually prepared for pharmaceutical or veterinary purposes are the citrate, 3C4H10N2.2C6H8O7 (i.e. containing 3 molecules of piperazine to 2 molecules of citric acid), and the adipate, C4H10N2.C6H10O4 (containing 1 molecule each of piperazine and adipic acid).Recommanded Product: 839712-12-8
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics